- Home
- IGMS vs VACH Comparison
IGMS vs VACH Comparison
Compare IGMS & VACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- VACH
- Stock Information
- Founded
- IGMS 1993
- VACH 2023
- Country
- IGMS United States
- VACH United States
- Employees
- IGMS N/A
- VACH N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- VACH
- Sector
- IGMS Health Care
- VACH
- Exchange
- IGMS Nasdaq
- VACH NYSE
- Market Cap
- IGMS 348.5M
- VACH 318.5M
- IPO Year
- IGMS 2019
- VACH 2024
- Fundamental
- Price
- IGMS $1.77
- VACH $10.07
- Analyst Decision
- IGMS Hold
- VACH
- Analyst Count
- IGMS 8
- VACH 0
- Target Price
- IGMS $6.14
- VACH N/A
- AVG Volume (30 Days)
- IGMS 779.9K
- VACH 76.5K
- Earning Date
- IGMS 03-06-2025
- VACH 01-01-0001
- Dividend Yield
- IGMS N/A
- VACH N/A
- EPS Growth
- IGMS N/A
- VACH N/A
- EPS
- IGMS N/A
- VACH N/A
- Revenue
- IGMS $2,918,000.00
- VACH N/A
- Revenue This Year
- IGMS $23.57
- VACH N/A
- Revenue Next Year
- IGMS $192.36
- VACH N/A
- P/E Ratio
- IGMS N/A
- VACH N/A
- Revenue Growth
- IGMS 57.64
- VACH N/A
- 52 Week Low
- IGMS $1.59
- VACH $10.12
- 52 Week High
- IGMS $22.50
- VACH $10.22
- Technical
- Relative Strength Index (RSI)
- IGMS 19.54
- VACH N/A
- Support Level
- IGMS $1.59
- VACH N/A
- Resistance Level
- IGMS $2.06
- VACH N/A
- Average True Range (ATR)
- IGMS 0.45
- VACH 0.00
- MACD
- IGMS -0.30
- VACH 0.00
- Stochastic Oscillator
- IGMS 3.27
- VACH 0.00
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About VACH VOYAGER ACQUISITION CORP.
Voyager Acquisition Corp is a blank check company.